197 related articles for article (PubMed ID: 15054036)
1. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
Casadevall N; Durieux P; Dubois S; Hemery F; Lepage E; Quarré MC; Damaj G; Giraudier S; Guerci A; Laurent G; Dombret H; Chomienne C; Ribrag V; Stamatoullas A; Marie JP; Vekhoff A; Maloisel F; Navarro R; Dreyfus F; Fenaux P
Blood; 2004 Jul; 104(2):321-7. PubMed ID: 15054036
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
4. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Oberg G; Osterborg A; Ost A
Blood; 1998 Jul; 92(1):68-75. PubMed ID: 9639501
[TBL] [Abstract][Full Text] [Related]
6. Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges.
Stasi R; Amadori S; Newland AC; Provan D
Blood; 2004 Oct; 104(7):2201; author reply 2201-2. PubMed ID: 15377575
[No Abstract] [Full Text] [Related]
7. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
Kelaidi C; Beyne-Rauzy O; Braun T; Sapena R; Cougoul P; Adès L; Pillard F; Lamberto C; Charniot JC; Guerci A; Choufi B; Stamatoullas A; Slama B; De Renzis B; Ame S; Damaj G; Boyer F; Chaury MP; Legros L; Cheze S; Testu A; Gyan E; Béné MC; Rose C; Dreyfus F; Fenaux P
Ann Hematol; 2013 May; 92(5):621-31. PubMed ID: 23358617
[TBL] [Abstract][Full Text] [Related]
8. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
Negrin RS; Stein R; Vardiman J; Doherty K; Cornwell J; Krantz S; Greenberg PL
Blood; 1993 Aug; 82(3):737-43. PubMed ID: 7687889
[TBL] [Abstract][Full Text] [Related]
9. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
Negrin RS; Stein R; Doherty K; Cornwell J; Vardiman J; Krantz S; Greenberg PL
Blood; 1996 May; 87(10):4076-81. PubMed ID: 8639764
[TBL] [Abstract][Full Text] [Related]
10. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
[TBL] [Abstract][Full Text] [Related]
11. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).
Greenberg PL; Sun Z; Miller KB; Bennett JM; Tallman MS; Dewald G; Paietta E; van der Jagt R; Houston J; Thomas ML; Cella D; Rowe JM
Blood; 2009 Sep; 114(12):2393-400. PubMed ID: 19564636
[TBL] [Abstract][Full Text] [Related]
12. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review.
Affentranger L; Bohlius J; Hallal M; Bonadies N
Crit Rev Oncol Hematol; 2019 Apr; 136():37-47. PubMed ID: 30878127
[TBL] [Abstract][Full Text] [Related]
14. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.
Hellström-Lindberg E; Birgegård G; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Merk K; Tangen JM; Winqvist I
Leuk Lymphoma; 1993 Oct; 11(3-4):221-8. PubMed ID: 7505147
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
[TBL] [Abstract][Full Text] [Related]
18. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638
[TBL] [Abstract][Full Text] [Related]
19. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol.
Ganser A; Maurer A; Contzen C; Seipelt G; Ottmann OG; Schadeck-Gressel C; Kolbe K; Haas R; Zander C; Reutzel R; Hoelzer D
Ann Hematol; 1996 Apr; 72(4):237-44. PubMed ID: 8624378
[TBL] [Abstract][Full Text] [Related]
20. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group.
Bessho M; Hirashima K; Asano S; Ikeda Y; Ogawa N; Tomonaga M; Toyama K; Nakahata T; Nomura T; Mizoguchi H; Yoshida Y; Niitsu Y; Kohgo Y
Eur J Haematol; 1997 Apr; 58(4):265-72. PubMed ID: 9186538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
